Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

famitinib

An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Famitinib binds to and inhibits several RTKs… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
In the last few years, the therapeutic approach for neuroendocrine neoplasms (NENs) has changed dramatically following the… Expand
2017
2017
AbstractBackgroundMetastatic colorectal cancer (mCRC) patients with progressive disease after all available standard therapies… Expand
Review
2016
Review
2016
ABSTRACT Introduction: Anti-angiogenetic agents are currently the standard of care in metastatic CRC patients. Bevacizumab… Expand
2015
2015
513 Background: Colorectal cancer (CRC) is the third most frequently diagnosed cancer and is the fifth leading cause of cancer… Expand
Review
2015
Review
2015
The 2015 Gastrointestinal Cancers Symposium (San Francisco, CA, USA; January 15–17) is the world-class conference co-sponsored by… Expand
  • table 1
2015
2015
Purpose: Famitinib is a novel tyrosine kinase inhibitor. We investigated the effects of famitinib on the radiosensitivity of… Expand
2014
2014
AbstractPurpose Hypothyroidism is a common adverse event in patients treated with anti-VEGFR-2 targeting agents and may be a… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
2013
2013
Famitinib is a novel multi‐targeted receptor tyrosine kinase inhibitor under development for cancer treatment. This study aims to… Expand
2013
2013
AbstractPurpose To evaluate the safety, tolerability, pharmacokinetics and antitumor activities of famitinib (famitinib l-malate… Expand
  • table 2
  • table 1
  • table 3
  • table 4
  • table 5
2013
2013
Background Famitinib is a novel and potent multitargeting receptor tyrosine kinase inhibitor. The phase I clinical study showed… Expand
  • table 1
  • figure 1
  • table 2